MX9805814A - Db, el receptor para leptina; acidos nucleicos que codifican el receptor, y sus usos. - Google Patents

Db, el receptor para leptina; acidos nucleicos que codifican el receptor, y sus usos.

Info

Publication number
MX9805814A
MX9805814A MX9805814A MX9805814A MX9805814A MX 9805814 A MX9805814 A MX 9805814A MX 9805814 A MX9805814 A MX 9805814A MX 9805814 A MX9805814 A MX 9805814A MX 9805814 A MX9805814 A MX 9805814A
Authority
MX
Mexico
Prior art keywords
receptor
leptin
nucleic acids
acids encoding
relates
Prior art date
Application number
MX9805814A
Other languages
English (en)
Inventor
Jeffrey M Friedman
Gwo-Hwa Lee
Ricardo Proenca
Ella Ioffe
Original Assignee
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/586,594 external-priority patent/US7084252B1/en
Application filed by Univ Rockefeller filed Critical Univ Rockefeller
Publication of MX9805814A publication Critical patent/MX9805814A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invencion se refiere a la identificacion de un receptor para un factor de seguridad que está implicado en la homeostasis de peso del cuerpo; Las mutaciones en este receptor están asociadas con los fenotipos obesos. En particular, la presente invencion se refiere a la identificacion y la caracterizacion del receptor para leptina, que incluye una forma soluble del receptor, que ocurre naturalmente, que se espera que module la actividad de la leptina; en particular que agonice la actividad de la leptina; la invencion se refiere además a losácidos nucleicos que codifican el receptor y a los métodos para usar el receptor, por ejemplo, para identificar los análogos de leptina, terapéuticamente, tal como en la terapia genética, o en forma soluble como un agonista o antagonista de la actividad de la leptina, o en diagnostico.
MX9805814A 1996-01-16 1998-07-16 Db, el receptor para leptina; acidos nucleicos que codifican el receptor, y sus usos. MX9805814A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/586,594 US7084252B1 (en) 1996-01-16 1996-01-16 DB, the receptor for leptin
US08/599,974 US7063958B1 (en) 1996-01-16 1996-02-14 Nucleic acids db, the receptor for leptin

Publications (1)

Publication Number Publication Date
MX9805814A true MX9805814A (es) 1998-12-31

Family

ID=27079758

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9805814A MX9805814A (es) 1996-01-16 1998-07-16 Db, el receptor para leptina; acidos nucleicos que codifican el receptor, y sus usos.

Country Status (12)

Country Link
US (1) US7063958B1 (es)
EP (1) EP0879286B1 (es)
JP (1) JP4285771B2 (es)
AT (1) ATE392473T1 (es)
AU (1) AU2244797A (es)
CA (1) CA2243446A1 (es)
DE (1) DE69738637T2 (es)
ES (1) ES2306456T3 (es)
IL (3) IL125353A (es)
MX (1) MX9805814A (es)
NZ (1) NZ511840A (es)
WO (1) WO1997026335A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310034B1 (en) 1993-05-21 2001-10-30 Ut-Battelle, Llc Agouti polypeptide compositions
US6001968A (en) * 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6287782B1 (en) * 1995-11-27 2001-09-11 Millennium Pharmaceuticals, Inc. Methods of using the Ob receptor to identify therapeutic compounds
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE69734096T2 (de) * 1996-01-04 2006-06-29 Amgen Inc., Thousand Oaks Rezeptor des ob-proteins und verwandte zusammensetzungen und verfahren
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US6281346B1 (en) * 1996-03-22 2001-08-28 Merck & Co., Inc. Rat ob-receptors and nucleotides encoding them
AU3640397A (en) * 1996-06-07 1998-01-05 Eli Lilly And Company Ob protein binding protein
AU4075897A (en) * 1996-08-16 1998-03-06 Roger Lallone A leptin binding protein and its use in methods for diagnosing and treating abnormalities of the endogenous leptin pathway
ID21861A (id) * 1996-09-20 1999-08-05 Hoechst Ag Penggunaan antagonis leptin untuk pengobatan daya tahan terhadap insulin dalam diabetes tipe ii
CA2273164A1 (en) 1996-12-02 1998-06-11 Merck & Co., Inc. Mutant ob receptors and nucleotides encoding them
AU7821798A (en) * 1997-06-09 1998-12-30 Regeneron Pharmaceuticals, Inc. Assay systems for leptin-enhancing agents
US6770444B2 (en) 1998-07-16 2004-08-03 Synaptic Pharmaceutical Corporation Methods of identifying or screening for agents that binds the Ob-Re
WO2000007014A2 (en) 1998-07-28 2000-02-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Leptin-mediated gene-induction
US6777388B1 (en) 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
AU767068B2 (en) * 1999-06-11 2003-10-30 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of leptin activity
EP1191945A4 (en) * 1999-06-11 2003-04-23 Baylor College Medicine METHODS AND COMPOSITIONS FOR CONTROLLING BONE FORMATION BY MODULATING LEPTIN ACTIVITY
WO2001090188A2 (en) 2000-05-22 2001-11-29 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Receptor-based interaction trap
ES2294048T3 (es) * 2000-11-14 2008-04-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Fragmento funcional de receptor de leptina.
US7235629B2 (en) * 2000-11-14 2007-06-26 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Functional fragment of the leptin receptor
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US20050255463A1 (en) * 2001-06-14 2005-11-17 Dephillipo John R Kits and methods for assessing leptin-mediated lipid metabolism
EP1812038A1 (en) 2004-11-18 2007-08-01 VIB vzw Fibronectin iii domain as leptin receptor antagonists
EA201991075A1 (ru) * 2016-11-08 2019-10-31 Антигенсвязывающие белки, которые проявляют антагонизм в отношении лептинового рецептора
CN112040980A (zh) 2018-04-06 2020-12-04 瑞泽恩制药公司 用于治疗代谢功能障碍或低瘦蛋白血症的瘦蛋白受体激动剂抗体

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014092A1 (en) 1989-05-18 1990-11-29 Cell Genesys, Inc. Single-strand site-directed modification of mammalian genes in vivo
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
ATE174058T1 (de) 1989-11-06 1998-12-15 Cell Genesys Inc Herstellung von proteinen mittels homologer rekombination
RU2128227C1 (ru) 1989-12-22 1999-03-27 Апплайд Резеч Системз АРС Холдинг Н.В. (NL) (Антильские острова) Способ активации транскрипционно-молчащего гена
CA2074825C (en) 1990-12-14 2005-04-12 Daniel J. Capon Chimeric chains for receptor-associated signal transduction pathways
WO1994005332A2 (en) * 1992-09-01 1994-03-17 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
IL107378A (en) * 1993-10-24 2005-05-17 Yeda Res & Dev SOLUBLE INTERFERON alpha-RECEPTOR, ITS PREPARATION AND USE
US5643748A (en) * 1994-09-14 1997-07-01 Progenitor, Inc. HU-B1.219, a novel human hematopoietin receptor
US5912123A (en) 1994-09-14 1999-06-15 Progenitor, Inc. Detection of the leptin receptor in reproductive organs and methods for regulating reproductive biology
CA2218529A1 (en) * 1995-05-08 1996-11-14 Chiron Corporation Nucleic acids for treating obesity
AUPN564195A0 (en) 1995-09-26 1995-10-19 Walter And Eliza Hall Institute Of Medical Research, The A novel haemopoietin receptor and genetic sequences encoding same
US6482927B1 (en) * 1995-11-27 2002-11-19 Millennium Pharmaceuticals, Inc. Chimeric proteins comprising the extracellular domain of murine Ob receptor
US6506877B1 (en) * 1995-11-27 2003-01-14 Millennium Pharmaceuticals, Inc. Ob receptor
DE69734096T2 (de) 1996-01-04 2006-06-29 Amgen Inc., Thousand Oaks Rezeptor des ob-proteins und verwandte zusammensetzungen und verfahren
AU721129B2 (en) * 1996-01-08 2000-06-22 Genentech Inc. WSX receptor and ligands
AU1833197A (en) 1996-01-18 1997-08-11 Progenitor, Inc. Detection of a leptin receptor variant and methods for regulating obesity
CA2246226A1 (en) 1996-02-22 1997-08-28 Merck & Co., Inc. Rat ob receptors and nucleotides encoding them
JP2000511406A (ja) 1996-04-22 2000-09-05 メルク エンド カンパニー インコーポレーテッド レプチンアッセイ
AU2408397A (en) 1996-04-30 1997-11-19 Otsuka Pharmaceutical Co., Ltd. Ob protein receptor genes and use of the same
WO1997042340A1 (en) 1996-05-06 1997-11-13 Merck & Co., Inc. Ob receptor isoforms and nucleic acids encoding them

Also Published As

Publication number Publication date
CA2243446A1 (en) 1997-07-24
IL125353A (en) 2009-07-20
JP4285771B2 (ja) 2009-06-24
NZ511840A (en) 2005-02-25
IL125353A0 (en) 1999-03-12
IL208750A0 (en) 2010-12-30
ATE392473T1 (de) 2008-05-15
EP0879286A1 (en) 1998-11-25
US7063958B1 (en) 2006-06-20
EP0879286B1 (en) 2008-04-16
IL195948A (en) 2010-12-30
ES2306456T3 (es) 2008-11-01
AU2244797A (en) 1997-08-11
DE69738637T2 (de) 2009-05-28
JP2000504938A (ja) 2000-04-25
WO1997026335A1 (en) 1997-07-24
DE69738637D1 (de) 2008-05-29

Similar Documents

Publication Publication Date Title
IL208750A0 (en) Isolated leptin receptor polypeptide
Villa et al. Variant estrogen receptor messenger RNA species detected in human primary hepatocellular carcinoma
WO1999060119A3 (en) Multivalent t cell receptor complexes
Chen et al. Molecular and pharmacological characterization of the mouse histamine H3 receptor
Nielsen et al. Interleukin‐2 induces tyrosine phosphorylation and nuclear translocation of stat3 in human T lymphocytes
IL141021A (en) Use of copolymer-like polypeptide-1 to prepare a drug to treat autoimmune diseases
MXPA03003902A (es) Polipeptidos de proquineticina, composiciones relacionadas y metodos.
WO1997021811A3 (en) Novel tyrosine kinase receptors and ligands
WO2001044177A3 (en) Somatostatin analogs, radiolabelled derivatives thereof and their use
Mills et al. Autoradiographic mapping of [3H] sumatriptan binding in cat brain stem and spinal cord
Stachowiak et al. Neural and hormonal regulation of the tyrosine hydroxylase gene in adrenal medullary cells: participation of c-fos and AP1 factors
DK0939809T3 (da) TIE-2 receptor-ligand (TIE ligand-4) og dens anvendelse
MX9702789A (es) Novedosas proteinas ligandos del dominio de la muerte del receptor tnf, e inhibidores de la union delos ligandos.
Rivera et al. Differential effect of chronic morphine on mRNA encoding adenylyl cyclase isoforms: relevance to physiological sequela of tolerance/dependence
Wada et al. Identification of ligand recognition sites in heat-stable enterotoxin receptor, membrane-associated guanylyl cyclase C by site-directed mutational analysis
Brar et al. An Ets motif in the proximal decidual prolactin promoter is essential for basal gene expression
Al-Dhaheri et al. Application of phosphorylation site-specific antibodies to measure nuclear receptor signaling: characterization of novel phosphoantibodies for estrogen receptor α
Lim et al. Cellular stress-related protein expression in Helicobacter pylori-infected gastric epithelial AGS cells
US20030166895A1 (en) Galanin receptor, nucleic acids, transformed cell and uses thereof
Bauer et al. Activation of topoisomerase I by poly [ADP-ribose] polymerase.
Sumiyoshi et al. Heterogenicity of ornithine decarboxylase during mouse colon carcinogenesis and in human colon tumors
Alokail et al. Quantitative comparison of PTH1R in breast cancer MCF7 and osteosarcoma SaOS‐2 cell lines
Matsumoto et al. Hypophosphorylation of Topoisomerase IIα in Etoposide (VP‐16)‐resistant Human Carcinoma Cell Lines Associated with Carboxy‐terminal Truncation
O'Bryant et al. Expression of nuclear receptor coactivators in androgen-responsive and-unresponsive motoneurons
Nagakawa et al. Vasoactive intestinal peptide (VIP) enhances the cell motility of androgen receptor-transfected DU-145 prostate cancer cells (DU-145/AR)

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees